Heart Failure

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.

Few data exist on how right ventricular fractional area change (RVFAC) may contribute to outcomes among patients hospitalized for heart failure, so that potential relationship was investigated in this new study from Japan.

Using chronotropic response as a reference, study authors from Japan investigated the potential influence of exercise-induced heart rate on cardiac output reserve and exercise capacity among a cohort of patients with heart failure with preserved ejection fraction (HFpEF).

Investigators from Toronto compared morbidity and mortality outcomes among patients with acute decompensated heart failure (ADHF) before and during the COVID-19 pandemic.

Using the Nationwide Inpatient Database for trends studied between 1993 and 2011, investigators from Columbia University Irving Medical Center evaluated hospitalization outcomes among patients with heart failure and comorbid gout.

In this study, Italian investigators evaluated how sacubitril/valsartan (Sac/Val) dose titration among older patients with heart failure with reduced ejection fraction (HFrEF) might affect reverse cardiac remodeling and if the success of up-titration can be predicted.

Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.

The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.

The long-term study also found persistent residual risk of heart failure even after smoking cessation

This new study, which the authors claim is the first to do so, investigated the relationship between COVID-19 vaccination status and survival outcomes among individuals with heart failure.

Sacubitril/valsartan reduced mean pulmonary artery pressure (mPAP) and improved lung congestion, functional capacity, and quality of life in a subset of patients with heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH) using a remote monitoring platform.

This new study, from Taiwan, investigated how menopause affects ventricular structure and function and its possible impact on heart failure among women.

Thirst outcomes were investigated among patients with stable heart failure (HF), due to the limited data available on this relationship and how it, along with fluid and sodium intake, influences clinical outcomes in this population.

This study evaluated levels of 4 biomarkers associated with heart failure with reduced ejection fraction (HFrEF) before and after treatment with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan.

Two periods of sacubitril/valsartan initiation were compared in a study population of patients with heart failure with reduced ejection fraction (HFrEF): less than 3 months or 3 or more months following first HFrEF diagnosis.

Infertility as a predisposing factor for heart failure (HF) was the subject of this new study evaluating outcomes among postmenopausal women.

In this study, investigators from Pennsylvania and New York evaluated outcomes among patients following their hospitalization for heart failure (HF) who did or did not participate in a remote monitoring program that included financial incentives for adherence.

In this study, outcomes were investigated among a cohort of patients with heart failure with reduced ejection fraction (HFrEF) who participated in a cardiac rehabilitation program post hospital discharge after they survived acute onset of HFrEF.

These investigators wanted to better understand the reasons for the increased risk for acute myocardial infarctions among young women, who have the largest increase in hospitalization for heart attacks.

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentration, prompted by growing interest in its use as a predictive biomarker for HF.

There may be a small, but not overwhelming, benefit for certain individuals aged 40 to 59 years who have a slightly elevated risk of future cardiovascular disease (CVD) to start taking aspirin, according to an update released by the US Preventive Services Task Force (USPSTF).

The FDA is increasing oversight of e-cigarettes and similar products that use synthetic nicotine; a lawsuit is brought over Philadelphia's reinstated mask mandate; a study shows drinking water may lower risk of heart failure.

This study investigated long-term cardiac-related mortality as it relates to incidence of perioperative adverse cardiac events (excluding death) in the first 30 days after surgery among a short of patients who underwent non–cardiac-related surgery.

Delayed diagnosis of wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) results in inappropriate treatments prior to diagnosis and worse clinical outcomes after diagnosis.

In this contributor piece, the connection between the complexities of mental health and heart disease in at-risk communities is explored, with the authors stressing the importance of risk factor evaluation and multidisciplinary patient education from both mental and physical health providers.

More than a quarter of patients experience disruptions and delays in treatment for chronic heart failure (CHF) after the initial prescription for sacubitril/valsartan was abandoned/rejected.

The Biden administration plans to expand Affordable Care Act (ACA) coverage to more families; new guidelines jointly announced by cardiology organizations for the treatment and prevention of heart failure; World Health Organization estimates that 99% of people worldwide are exposed to poor air quality.

This new analysis of data from the Swedish Heart Failure Registry involved an investigation into the relationship between therapy count and dosing on mortality and morbidity among patients with heart failure with reduced ejection fraction (HFrEF).

Two studies presented at the annual meeting of the American College of Cardiology show the safety and effectiveness of regular coffee consumption in regard to cardiovascular disease and heart disease, as well as mortality.

This study enrolled 80 middle-aged patients with stage A heart failure and evaluated them for improvements in several cardiovascular and metabolic risk factors through high-intensity interval training (HIIT) for 1 year and omega-3 fatty acid supplementation.